Shawn Lee, MD
Pulmonary Disease · Oklahoma City, OKNPI 1285733345
Payments from drug & device makers
Across 115 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$301
- Sunovion Pharmaceuticals Inc.$231
- AbbVie$189
- AstraZeneca$139
- Inogen, Inc.$119
- Novartis$118
- plus $680 from 17 others
What the payments were for
- Food & beverage$1,778100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 20 | $301 |
| Sunovion Pharmaceuticals Inc. | 25 | $231 |
| AbbVie(2 entities) | 7 | $189 |
| AstraZeneca(2 entities) | 9 | $139 |
| Inogen, Inc. | 11 | $119 |
| Novartis | 7 | $118 |
| Boehringer Ingelheim | 6 | $104 |
| Sanofi | 4 | $92 |
| Genentech USA, Inc. | 4 | $67 |
| Baxter Healthcare | 2 | $50 |
| Harmony Biosciences LLC | 3 | $48 |
| Merck | 3 | $46 |
| Insmed, Inc. | 3 | $41 |
| Regeneron Healthcare Solutions, Inc. | 2 | $41 |
| Johnson & Johnson | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Amgen | 1 | $23 |
| Philips North America LLC | 1 | $22 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Pulmonx Corporation | 1 | $18 |
| Gilead | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $16 |
How this compares
$1,778 in reported general payments places this provider in the 45th percentile of 133 pulmonary disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $29,031 |
| Spiriva RespimatTiotropium Bromide | 34 | $17,425 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,772 |
| Advair DiskusFluticasone Propion/Salmeterol | 21 | $4,470 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,655 |
| AsmanexMometasone Furoate | 17 | $2,374 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $894 |
| Ventolin HfaAlbuterol Sulfate | 12 | $675 |
| Montelukast Sodium | 36 | $480 |
| Fluticasone Propionate | 12 | $187 |
| Prednisone | 17 | $61 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $301 | $29,03139 claims |
| Boehringer IngelheimSpiriva Respimat | $104 | $17,42534 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $139 | $13,42729 claims |
| MerckAsmanex | $46 | $2,37417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 133 pulmonary disease providers in Oklahoma.
Other pulmonary disease in Oklahoma City
- John KingreyOklahoma City$2.4M
- Jad KebbeOklahoma City$1.5M
- Karen AllenOklahoma City$202K
- Robert GordonOklahoma City$160K
- Nicholas ShelburneOklahoma City$102K
- Tony AbdoOklahoma City$91K
- Fawad ChaudryOklahoma City$80K
- Loan NguyenOklahoma City$76K
- Maroun TawkOklahoma City$62K
- Adam PrzebindaOklahoma City$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.